AU5854799A - Novel treatment of neurodegenerative diseases - Google Patents

Novel treatment of neurodegenerative diseases

Info

Publication number
AU5854799A
AU5854799A AU58547/99A AU5854799A AU5854799A AU 5854799 A AU5854799 A AU 5854799A AU 58547/99 A AU58547/99 A AU 58547/99A AU 5854799 A AU5854799 A AU 5854799A AU 5854799 A AU5854799 A AU 5854799A
Authority
AU
Australia
Prior art keywords
neurodegenerative diseases
novel treatment
novel
treatment
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58547/99A
Inventor
Osborne F. X. Almeida
Maria Griselda Canteros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of AU5854799A publication Critical patent/AU5854799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU58547/99A 1998-08-25 1999-08-25 Novel treatment of neurodegenerative diseases Abandoned AU5854799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98116035 1998-08-25
EP98116035 1998-08-25
PCT/EP1999/006241 WO2000010546A2 (en) 1998-08-25 1999-08-25 D-arginine for the treatment of neorodegenerative diseases

Publications (1)

Publication Number Publication Date
AU5854799A true AU5854799A (en) 2000-03-14

Family

ID=8232511

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58547/99A Abandoned AU5854799A (en) 1998-08-25 1999-08-25 Novel treatment of neurodegenerative diseases

Country Status (2)

Country Link
AU (1) AU5854799A (en)
WO (1) WO2000010546A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265825A1 (en) * 2001-01-19 2004-12-30 Boris Tartakovsky Methods and compositions for diagnosing and treating a subject having depression
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
WO2006126199A2 (en) * 2005-05-24 2006-11-30 Fund For Medical Research Development Of Infrastructure & Health Services Rambam Medical Center Methods and compositions for treating schizophrenia
JP7078410B2 (en) * 2018-01-31 2022-05-31 株式会社明治 A composition containing D-arginine and a method for producing the same.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1201511B (en) * 1985-12-23 1989-02-02 Italfarmaco Spa CITOPROTECTIVE DERIVATIVES IN ISCHEMIC-BASED DISEASES, THEIR PREPARATION AND COMPOSITIONS THAT CONTAIN THEM
DE4311806A1 (en) * 1993-04-03 1994-10-06 Schering Ag Use of arginine derivatives as quisqualate antagonists
GB9312204D0 (en) * 1993-06-14 1993-07-28 Zeneca Ltd Therapeutic composition

Also Published As

Publication number Publication date
WO2000010546A2 (en) 2000-03-02
WO2000010546A3 (en) 2003-04-17

Similar Documents

Publication Publication Date Title
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
AU3673499A (en) Hydrogel for the therapeutic treatment of aneurysms
AU3891299A (en) Combination therapy for treatment of depression
AU2001257903A1 (en) Method for treatment of neurodegenerative diseases
AU3596199A (en) Treatment of celiac disease
AU3784999A (en) Methods for treatment of pain
AU1356201A (en) Treatment of hyperproliferative disorders
AU1697197A (en) Immunoconjugate for the treatment of aids
AU3896900A (en) Treatment of pain
AU3596797A (en) Methods for the treatment of apolipoprotein e related diseases
AU4215499A (en) Treatment of neurodegenerative diseases
AUPO871397A0 (en) Improved treatment of hides
AU7106300A (en) Treatment of skin disorders
AU1197599A (en) Detection of neurodegenerative diseases
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU5854799A (en) Novel treatment of neurodegenerative diseases
AU5699396A (en) Compositions for the treatment of skin conditions
AU1405001A (en) Treatment of diseases
AU2754997A (en) The treatment of plant diseases
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AUPP229598A0 (en) Treatment of sunburn
AU9082698A (en) Treatment of inflammatory conditions
AU2382601A (en) Novel method of treatment
AU7545998A (en) Treatment of osteoporosis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase